Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers

Shangwei Ning1,†, Jizhou Zhang1,†, Peng Wang1, Hui Zhi1, Jianjian Wang2, Yue Liu1, Yue Gao1, Maoni Guo1, Ming Yue1, Lihua Wang2,* and Xia Li1,*

1College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China and
2Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China

Received July 29, 2015; Revised September 19, 2015; Accepted October 9, 2015

ABSTRACT

Lnc2Cancer (http://www.bio-bigdata.net/lnc2cancer) is a manually curated database of cancer-associated long non-coding RNAs (lncRNAs) with experimental support that aims to provide a high-quality and integrated resource for exploring lncRNA deregulation in various human cancers. lncRNAs represent a large category of functional RNA molecules that play a significant role in human cancers. A curated collection and summary of deregulated lncRNAs in cancer is essential to thoroughly understand the mechanisms and functions of lncRNAs. Here, we developed the Lnc2Cancer database, which contains 1057 manually curated associations between 531 lncRNAs and 86 human cancers. Each association includes lncRNA and cancer name, the lncRNA expression pattern, experimental techniques, a brief functional description, the original reference and additional annotation information. Lnc2Cancer provides a user-friendly interface to conveniently browse, retrieve and download data. Lnc2Cancer also offers a submission page for researchers to submit newly validated lncRNA-cancer associations. With the rapidly increasing interest in lncRNAs, Lnc2Cancer will significantly improve our understanding of lncRNA deregulation in cancer and has the potential to be a timely and valuable resource.

INTRODUCTION

Cancer is a leading cause of death worldwide and has emerged as a major public health problem in many countries (1). Cancer is a complex disease involving multiple levels of alterations, including genetic, epigenetic and transcriptomic alterations (2). One of the most important tasks in cancer research is to understand the molecular mechanisms underlying these alterations.

In recent years, increasing evidence has suggested that a novel class of non-coding RNA, long non-coding RNA (lncRNA), is commonly altered at various stages of cancer progression (3,4). lncRNAs are a class of pervasively transcribed RNA molecules with a length of more than 200 nucleotides that do not encode proteins (5). Studies have indicated that lncRNAs play critical roles in a wide range of biological processes (6,7). Due to their functional significance, several databases have been developed to store lncRNA-related information. For example, NONCODE (8), lncRNADb (9), LNCipedia (10) and LncRNAWiki (11) integrate lncRNA data obtained from different sources. ChIPBase (12) is focused on the transcriptional regulation of miRNAs and lncRNAs. DIANA-LncBase (13) identifies miRNA-lncRNA interactions. LncRNADisease (14), lncRNASNP (15) and LincSNP (16) contain different lncRNA and disease associations. These databases are crucial for deciphering lncRNA functions in human cancers. However, our knowledge of cancer-related lncRNAs remains limited. In particular, a public resource of high-quality curated cancer-associated lncRNAs remains unavailable.

Recent publications of large-scale cancer genomic datasets, such as The Cancer Genome Atlas (17), provide an opportunity to investigate cancer-related lncRNAs in a large sample (18,19). In addition to these large-scale studies, studies focused on individual or specific lncRNA in various cancers are rapidly emerging (20,21). Currently, accumulating evidence suggests that the deregulation of lncRNAs plays an important role in human cancers (22). However, these experimentally supported lncRNA-cancer associations are hidden in thousands of published studies. These fragmented and even inconsistent publications are an obstacle to characterizing lncRNA functions in cancer from a global view. In addition, several cancer-specialized

†To whom correspondence should be addressed. Tel: +86 451 8661 5922; Fax: +86 451 8661 5922; Email: lixia@hrbmu.edu.cn
Correspondence may also be addressed to Lihua Wang. Email: wanglh211@163.com

© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
databases have been published that focus on some important topics. For example, COSMIC (23) collects cancer genes and mutations, MethyCancer (24) and PubMeth (25) aim to investigate DNA methylation in cancer, and miRCan (26) provides literature-supported microRNA and cancer associations; however, no resource is currently devoted to collecting the latest and experimentally supported lncRNA-cancer associations.

To address this gap, we developed a database, called Lnc2Cancer, to collect and integrate cancer-associated lncRNAs into a comprehensive resource. All lncRNA-cancer associations in the Lnc2Cancer are experimentally supported and manually curated from the published literature. The current version of Lnc2Cancer documents 1057 manually curated associations between 531 lncRNAs and 86 human cancers. We hope that this elaborate database specially designed for cancer and lncRNA could serve as an important catalyst for future research.

DATA COLLECTION AND DATABASE CONTENT

To ensure the highest quality in the data collection process, all Lnc2Cancer entries were manually collected through several steps as previously described (27–29). First, we searched the PubMed database (30) with a list of keywords, such as ‘lncRNA cancer,’ ‘long non-coding RNA cancer,’ ‘lncRNA tumor,’ ‘long non-coding RNA tumor,’ ‘lncRNA neoplasm,’ and ‘long non-coding RNA neoplasm.’ We downloaded all published literature describing the associations between lncRNAs and human cancers. Second, we extracted experimentally supported lncRNA-cancer associations ‘by hand,’ that is, by manually curating from published papers. All selected studies were reviewed by at least two researchers. In this step, we retrieved the lncRNA and cancer name, sequence and positional information of the lncRNA, experimental techniques (e.g., microarray, Northern blot, qRT-PCR), experimental samples (cell line and/or tissue), expression patterns of lncRNA (upregulated or downregulated), hyperlinks to the PubMed database (PubMed ID, year of publication, title of paper) and a brief functional description of lncRNA from the original studies. In particular, we have referred to previous studies and selected lncRNA-cancer associations for manual curation using strict criteria (31). We only collected high-quality associations with multiple lines of strong experimental evidence, experimentally confirmed by RNAi, in vitro knockdown, Western blot, qRT-PCR or luciferase reporter assays. Third, all selected studies were rechecked for the lncRNA names and cancers, and some names were replaced with official or recommended names. In this step, we also collected other names, including aliases and synonyms, for lncRNAs. To make the lncRNA names more complete and consistent with other databases, we have provided both the identifiers and links for the lncRNAs present in the Ensembl and RefSeq database. Finally, we used a standardized classification scheme, the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), to annotate each cancer type.

After completing the above processes, more than 1500 published papers were systematically reviewed, and a total of 1057 associations between 531 lncRNAs and 86 human cancers were manually curated. Moreover, we provided useful links to other databases, including lncRNAs in GenBank, HGNC, lncRNAdb and NONCODE and cancers in the OMIM and COSMIC databases, among others. We also provided several links to web-based computational tools to annotate lncRNA functions in cancer, such as LncRNA2Function (32) and Co-LncRNA (33), which allows users to identify GO annotations and KEGG pathways that might be affected by single or multiple lncRNAs.

Finally, all data in Lnc2Cancer were stored and managed using MySQL (version 5.5.58). The web interfaces were built in JSP. The data processing programs were written in Java (version 1.6.0), and the web services were built using Apache Tomcat. The Lnc2Cancer database is freely available at http://www.bio-bigdata.net/lnc2cancer and http://www.bio-bigdata.com/lnc2cancer.

USER INTERFACE

Lnc2Cancer provides a user-friendly web interface that enables users to browse, search and retrieve all lncRNA-cancer associations in the database (Figure 1). In the ‘Browse’ page, users can browse Lnc2Cancer by clicking a specific lncRNA or cancer name, and a list of matched entries is returned. In the ‘Search’ page, Lnc2Cancer allows users to search by lncRNA name and alternative name, cancer name or both. Lnc2Cancer offers fuzzy keyword searching capabilities, facilitating searches by returning the closest possible matching records. Lnc2Cancer provides an option in the ‘Search’ page that allows users to filter associations by certain experimental methods. Lnc2Cancer also offers a submission page that enables researchers to submit novel experimentally supported lncRNA-cancer associations. Once approved by the submission review committee, the submitted record will be included in the update release. In addition, all data in the database can be downloaded in the ‘Download’ page, and a detailed tutorial showing users how to use Lnc2Cancer is available on the ‘Help’ page.

FUTURE EXTENSIONS

More recently, high-throughput technologies, such as next-generation sequencing, have produced extensive data on cancer biology, and the number of validated cancer-associated lncRNAs will continue to increase in the future. These advances in research will provide the opportunity to further extend Lnc2Cancer. We will continue to manually curate newly validated lncRNA-cancer associations and update the database every 2 months. We will incorporate new tools and functional annotations as well as more data sources to improve the utility and content coverage of this database. In addition, several recent large-scale RNA-sequencing datasets have generated a large number of lncRNA-cancer associations (34). Although there is often no further strong experimental evidence to confirm these associations, they also have potential value for cancer study. We will develop novel methods to filter these associations in future studies.
DISCUSSION AND CONCLUSION

Emerging evidence suggests that aberrant expression of lncRNAs plays a critical role in human cancers. Because most cancer-related lncRNAs are identified in independent studies that have been performed over a period of many years, a curated collection of these lncRNAs will provide researchers with a vital resource for cancer research. Currently, there are several databases that can provide lncRNA-cancer associations for researchers (Supplementary Table S1). For example, the lncRNASNP (15) and LineSNP (16) databases store a number of cancer-associated SNPs in human lncRNAs. However, these lncRNA-cancer associations were inferred by computational methods and without direct experimental evidence. To the best of our knowledge, only one database, LncRNADisease (14), partially addresses the needs of cancer research. However, in the current version of LncRNADisease, there are 492 cancer-related entries that include only 128 human lncRNAs and 55 cancer types, and there are no explicit descriptions of the experimental techniques to find these associations. Thus, we developed Lnc2Cancer, a cancer-specialized database that provides a comprehensive resource on lncRNA dysregulation in various human cancers.

In addition to including a greater number of lncRNA-cancer associations, Lnc2Cancer has several advanced features that distinguish it from previous studies. For example, by searching Lnc2Cancer using ‘HOTAIR,’ a well-known human lncRNA, we found that the expression of HOTAIR is ‘upregulated’ in almost all cancer types, and this finding is supported by multiple lines of strong experimental evidence. In addition, Lnc2Cancer provides functional information on lncRNAs in cancer. For example,
Figure 2. Network and distribution of cancers and IncRNAs in Lnc2Cancer. (A) Human IncRNA-cancer bipartite network. Circles and rectangles correspond to IncRNAs and cancers, respectively, and the lines correspond to experimentally supported associations. The size of the nodes corresponds to the nodes’ degree. The ten cancers with the highest connectivity are colored, whereas other cancers are shown in gray. Distribution of the ten IncRNAs (B) and cancers (C) with the highest connectivity in bipartite network. Abbreviations: HCC (hepatocellular carcinoma), GC (gastric cancer), CRC (colorectal cancer), BC (breast cancer), NSCLC (non-small-cell lung cancer), PRC (prostate cancer), LAC (lung adenocarcinoma), LC (lung cancer), ESCC (esophageal squamous-cell carcinoma), PAC (pancreatic cancer).
searching Lnc2Cancer using both ‘HOTAIR’ and ‘cervical cancer,’ Lnc2Cancer shows that high HOTAIR expression in cervical cancer is correlated with lymph node metastasis and reduced overall survival and that HOTAIR regulates the expression of vascular endothelial growth factor, matrix metalloproteinase-9 and epithelial-to-mesenchymal transition-related genes, which are important for cell motility and metastasis (35). Lnc2Cancer indicates that these functional roles of HOTAIR are supported both in cell lines (SiHa, HeLa, Caski) and in cervical cancer tissue, which may be especially useful for cancer specialists and biologists.

By analyzing the data from Lnc2Cancer, we could find some important principles behind a large, complex and integrated resource. We constructed an IncRNA-cancer bipartite network (Figure 2A) in which the nodes denote IncRNAs or cancers and the lines correspond to experimentally supported associations between IncRNAs and cancers. We also list the ten most highly connected nodes in this bipartite network, including IncRNAs and cancers (Figure 2B and C, respectively). Previous studies have shown that if a node has more links within a given network, then loss of this node would generally greatly impact network behavior (36). We found that the cancer with the highest connectivity is hepatocellular carcinoma, which is associated with 86 IncRNAs. For IncRNAs, HOTAIR is the most highly connected node, which is associated with 35 cancers, thus providing further evidence for the importance of this IncRNA in human cancers (37). In addition, we counted the number of published papers each year that reported IncRNA-cancer associations and found that the publications generally increase dramatically (Supplementary Figure S1). Especially from 2012 to 2014, the number of publications increased in an exponential manner, suggesting that research on IncRNA-cancer associations has become a hot topic in recent years, thus providing us with tremendous power to develop a special-purpose repository to document these valuable data.

In summary, Lnc2Cancer not only provides more than 1000 manually curated IncRNA-cancer associations with experimental support but also offers global insights into IncRNA functions in human cancers. This unique and cancer-specialized database created here will be useful for future research.

**SUPPLEMENTARY DATA**

**Supplementary Data** are available at NAR Online.

**FUNDING**

National High Technology Research and Development Program of China [863 Program, 2014AA021102 in part]; National Program on Key Basic Research Project [973 Program, 2014CB910504]; National Natural Science Foundation of China [91439117, 61473106, 81171122 and 31401090]; Postdoctoral Science Foundation of China [2015M571432]; Postdoctoral Foundation of Heilongjiang Province [LBH-Z14148].

**Conflict of interest statement.** None declared.

**REFERENCES**

1. Siegel,R., Ma,J., Zou,Z. and Jemal,A. (2014) Cancer statistics, 2014. CA Cancer J. Clin., 64, 9–29.
2. Hanahan,D. and Weinberg,R.A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646–674.
3. Yuan,J.H., Yang,F., Wang,F., Ma,J.Z., Gao,Y.J., Tao,Q.F., Liu,F., Pan,W., Wang,T.T., Zhou,C.C. et al. (2014) A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell, 25, 666–681.
4. Prensner,J.R., Iyer,M.K., Sahu,A., Asangani,I.A., Cao,Q., Patel,L., Vergara,I.A., Davicioni,E., Erho,N., Ghadessi,M. et al. (2013) The long non-coding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet., 45, 1392–1398.
5. Flintoft,L. (2013) Non-coding RNA: Structure and function for IncRNAs. Nat. Rev. Genet., 14, 598.
6. Fatica,A. and Bozzoni,I. (2014) Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet., 15, 7–21.
7. Batista,P.J. and Chang,H.Y. (2013) Long non-coding RNAs: cellular address codes in development and disease. Cell, 152, 1298–1307.
8. Xin,C., Yuan,J., Li,H., Li,M., Zhang,G., Bu,D., Zhu,W., Wu,W., Shen,R. and Zhao,Y. (2014) NONCODEv4: exploring the world of long non-coding RNA genes. Nucleic Acids Res., 42, D989–D993.
9. Quek,X.C., Thomson,D.W., Maag,J.L., Bartonicek,N., Signal,B., Clark,M.B., Gloss,B.S. and Dinger,M.E. (2015) IncRNAdb v2.0: expanding the reference database for functional long non-coding RNAs. Nucleic Acids Res., 43, D168–D173.
10. Volders,P.J., Verheggen,K., Menschaert,G., Vandepoele,K., Martens,L., Vandesompele,J. and Mestdagh,P. (2015) An update on LNCPedia: a database for annotated human IncRNA sequences. Nucleic Acids, 43, D174–D180.
11. Ma,L., Li,A., Zou,D., Xie,X., Xia,L., Yu,J., Bujic,V.B. and Zhang,Z. (2015) LncRNAWiki: harnessing community knowledge in collaborative curation of human long non-coding RNAs. Nucleic Acids Res., 43, D187–D192.
12. Yang,J.H., Li,J.H., Jiang,S., Zhou,H. and Qu,L.H. (2013) ChiPBase: a database for decoding the transcriptional regulation of long non-coding RNA and macroRNA genes from ChIP-Seq data. Nucleic Acids Res., 41, D177–D181.
13. Parasevopoulou,M.D., Georgakilas,G., Kostoulas,N., Reczko,M., Maragakis,M., Dalamagas,T.M. and Hatzigeorgiou,A.G. (2013) DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res., 41, D239–D245.
14. Chen,G., Wang,Z., Wang,D., Qiu,C., Liu,M., Chen,X., Zhang,Q., Yan,G. and Cui,Q. (2015) LncRNA Disease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res., 43, D983–D986.
15. Gong,J., Liu,W., Zhang,J., Xiao,X. and Guo,A.Y. (2014) IncRNAsNP: a database of SNPs in IncRNAs and their potential functions in human and mouse. Nucleic Acids Res., 43, D181–D186.
16. Ning,S., Zhao,Z., Ye,J., Wang,P., Zhi,H., Li,R., Wang,T. and Li,X. (2014) LincSNP: a database of linking disease-associated SNPs to human large intergenic non-coding RNAs. BMC Bioinformatics, 15, 152.
17. Weinstein,J.N., Collisson,E.A., Mills,G.B., Shaw,K.R., Ozenberger,B.A., Ellrott,K., Shmulevich,I., Sander,C. and Stuart,J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet., 45, 1113–1120.
18. Wang,P., Ning,S., Zhang,Y., Li,R., Ye,J., Zhao,Z., Zhi,H., Wang,T., Guo,Z. and Li,X. (2015) Identification of IncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer. Nucleic Acids Res., 43, 3478–3489.
19. Du,Z., Fei,T., Verbaak,R.G., Su,Z., Zhang,Y., Brown,M., Chen,Y. and Liu,X.S. (2013) Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat. Struct. Mol. Biol., 20, 908–913.
20. Prensner,J.R., Chen,W., Iyer,M.K., Cao,Q., Ma,T., Han,S., Sahu,A., Malik,R., Wilder-Romans,K., Navone,N. et al. (2014) PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. *Cancer Res.*, **74**, 1651–1660.

21. Xiang,J.F., Yin,Q.F., Chen,T., Zhang,Y., Zhang,X.O., Wu,Z., Zhang,S., Wang,H.B., Ge,J., Lu.X. et al. (2014) Human colorectal cancer-specific CCAT1-L IncRNA regulates long-range chromatin interactions at the MYC locus. *Cell Res.*, **24**, 513–531.

22. Harries,L.W. (2012) Long non-coding RNAs and human disease. *Biochim Soc. Trans.*, **40**, 902–906.

23. Forbes,S.A., Beare,D., Gunasekaran,P., Leung,K., Bindal,N., Boutselakis,H., Ding,M., Bamford,S., Cole,C., Ward,S. et al. (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic Acids Res.*, **43**, D805–D811.

24. Harries,L.W. (2012) Long non-coding RNAs and human disease. *Biochim Soc. Trans.*, **40**, 902–906.

25. He,X., Chang,S., Zhang,J., Zhao,Q., Xiang,H., Kusonmano,K., Yang,L., Sun,Z.S., Yang,H. and Wang,J. (2008) MethyCancer: the database of human DNA methylation and cancer. *Nucleic Acids Res.*, **36**, D836–D841.

26. Xie,B., Ding,Q., Han,H. and Wu,D. (2013) miRCancer: a microRNA-cancer association database constructed by text mining on literature. *Bioinformatics*, **29**, 638–644.

27. Hsu,S.D., Tseng,Y.T., Shrestha,S., Lin,Y.L., Khaleel,A., Chou,C.H., Chu,C.F., Huang,H.Y., Lin,C.M., Ho,S.Y. et al. (2014) miRTarBase update 2014: an information resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res.*, **42**, D78–D85.

28. Jiang,Q., Wang,Y., Hao,Y., Juan,L., Teng,M., Zhang,X., Li,M., Wang,G. and Liu,Y. (2009) miR2Disease: a manually curated database for microRNA deregulation in human disease. *Nucleic Acids Res.*, **37**, D98–D104.

29. Li.Y., Qiu.C., Tu.J., Geng.B., Yang.J., Jiang.T. and Cui.Q. (2014) HMDD v2.0: a database for experimentally supported human microRNA and disease associations. *Nucleic Acids Res.*, **42**, D1070–D1074.

30. Coordinators,N.R. (2015) Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.*, **43**, D6–D17.

31. Hsu,S.D., Lin,F.M., Wu,W.Y., Liang,C., Huang,W.C., Chan,W.L., Tsai,W.T., Chen,G.Z., Lee,C.J., Chiu,C.M. et al. (2011) miRTarBase: a database curates experimentally validated microRNA-target interactions. *Nucleic Acids Res.*, **39**, D163–D169.

32. Jiang,Q., Ma,R., Wang,J., Wu,X., Jin,S., Peng,J., Tan,R., Zhang,T., Li,Y. and Wang,Y. (2015) LncRNA2Function: a comprehensive resource for functional investigation of human lncRNAs based on RNA-seq data. *BMC Genomics*, **16**(Suppl. 3), S2.

33. Zhao,Z., Bai,J., Wu,A., Wang,Y., Zhang,J., Wang,Z., Li,Y., Xu,J. and Li,X. (2015) Co-LncRNA: investigating the lncRNA combinatorial effects in GO annotations and KEGG pathways based on human RNA-Seq data. *Database (Oxford)*, **2015**, doi:10.1093/database/bav082.

34. Iyer,M.K., Niknafs,Y.S., Malik,R., Singhal,U., Sahu,A., Hosono,Y., Barrette,T.R., Prensner,J.R., Evans,J.R., Zhao,S. et al. (2015) The landscape of long noncoding RNAs in the human transcriptome. *Nat. Genet.*, **47**, 199–208.

35. Kim,H.J., Lee,D.W., Yim,G.W., Nam,E.J., Kim,S., Kim,S.W. and Kim,Y.T. (2015) Long non-coding RNA HOTAIR is associated with human cervical cancer progression. *Int. J. Oncol.*, **46**, 521–530.

36. Pelaez,N. and Carthew,R.W. (2012) Biological robustness and the role of microRNAs: a network perspective. *Curr. Top. Dev. Biol.*, **99**, 237–255.

37. Hajjari,M. and Salavaty,A. (2015) HOTAIR: an oncogenic long non-coding RNA in different cancers. *Cancer Biol. Med.*, **12**, 1–9.